SCHEDULE: Sphera Funds Discloses 7.78% Stake in ProMIS Neurosciences

Sphera Funds Management and its affiliates reported a 7.78% beneficial ownership stake in ProMIS Neurosciences Inc., including common shares and warrants, following a recent reverse stock split.

Summary

• Sphera Funds Management Ltd., Sphera Global Healthcare GP Ltd., and Sphera Global Healthcare Management LP collectively beneficially own 180,697.52 Common Shares of ProMIS Neurosciences Inc.
• This ownership represents 7.78% of the total class of securities outstanding.
• The percentage is calculated based on approximately 2,152,444 Common Shares outstanding after a one-for-twenty-five reverse stock split, effective November 28, 2025.
• The beneficial ownership includes 168,890 warrants, each currently exercisable into one Common Share.
• Specific holdings include 31,637.80 warrants (1.36%) held by Sphera Global Healthcare Master Fund and 11,807.48 Common Shares plus 137,252.24 warrants (6.42%) held by Sphera Biotech Master Fund, L.P.
• Sphera Global Healthcare Management LP acts as the investment manager for both funds, and its general partner, Sphera Global Healthcare GP Ltd., is 90% owned by Sphera Funds Management Ltd.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It is a standard regulatory disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or prospects.

Positives

• NA

Negatives

• NA

Risks

• The reporting persons disclaim beneficial ownership of any securities covered by this statement and state that the filing should not be construed as an admission of beneficial ownership.
• The reporting persons and other entities named in the Schedule 13G may be deemed to constitute a 'group' for purposes of Section 13(d) of the Securities Exchange Act of 1934, though they disclaim the existence of any such group.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding the issuer's future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors holding more than 5% of a company's stock, indicating passive investment intent. For a biotechnology company like ProMIS Neurosciences, such filings provide transparency on significant shareholder positions, which can be of interest to other investors tracking institutional confidence in the sector. The mention of a reverse stock split suggests the company may have been addressing share price concerns or preparing for a new strategic phase, a common occurrence in the volatile biotech industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially influencing market perception and liquidity.
• Investment Professionals: Offers insight into institutional interest in ProMIS Neurosciences, which can inform investment strategies.

Key Dates

Keywords

ProMIS Neurosciences Inc., Sphera Funds Management, Beneficial Ownership, Schedule 13G, Common Shares, Warrants, Reverse Stock Split, Biotechnology, Neuroscience, Institutional Investor